Skip to main content
. 2006 Feb 25;34(4):1205–1215. doi: 10.1093/nar/gkj521

Figure 3.

Figure 3

P-CREB/ATF and CBP/p300 occupy human FMR1 in vivo. (A) ChIP was carried out with either anti-P-CREB antibody or (B) antibodies to CBP and p300, or non-specific rabbit IgG [N.S. in both (A and B)]. PCR was performed to amplify the FMR1 and c-fos promoters in normal and fragile X cells (left). Occupancy of p300 was quantified by real-time PCR of an independent set of triplicate IPs (right); error bars represent ±1 standard deviation.